Caring Brands (NASDAQ:CABR) Posts Quarterly Earnings Results

Caring Brands (NASDAQ:CABR) issued its earnings results on Thursday. The company reported ($0.10) earnings per share (EPS) for the quarter, FiscalAI reports.

Caring Brands Trading Up 3.8%

CABR traded up $0.05 on Friday, hitting $1.36. The company had a trading volume of 8,246 shares, compared to its average volume of 108,136. The business’s fifty day simple moving average is $1.34 and its 200 day simple moving average is $1.12. The company has a quick ratio of 5.62, a current ratio of 5.66 and a debt-to-equity ratio of 0.03. Caring Brands has a 12-month low of $0.71 and a 12-month high of $5.35. The company has a market cap of $12.36 million and a PE ratio of -2.12.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Caring Brands stock. Jane Street Group LLC bought a new stake in shares of Caring Brands, Inc. (NASDAQ:CABR) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 34,446 shares of the company’s stock, valued at approximately $30,000. Jane Street Group LLC owned approximately 0.25% of Caring Brands as of its most recent SEC filing.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Caring Brands from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 11th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Caring Brands has an average rating of “Sell”.

Caring Brands Company Profile

We are a wellness consumer products company. We offer several over-the-counter, or (OTC) and cosmetic, consumer products. Our method of operation is to ensure that (1) the mechanism of action of all products is established, (2) efficacy is determined through controlled clinical trials, (3) products are protected by issued and filed patents, and (4) products have acceptable commercial stability. Prior to its Q3 2022 commercial launch in India as a treatment for vitiligo and psoriasis, Photocil was briefly launched in the United States markets from December 2022 until February 2023, however, was subsequently removed from the market due to insufficient sales resulting from the lack of a dedicated sales and marketing team.